Regnum Corp. (RGMP)

[Big Brother]

Ever since Wookey originally purchased it, RGMP has essentially been a shell company. Why they never changed the status, I don't know.... but it's value is as a public vehicle, these rarely have any cash or assets of any kind(beyond NOLs), or great balance sheets......this isn't a SPAC.

We have yet to see what kind of value these rights, or licenses have, which have been acquired here. Has CYDY ever posted any potential revenue forecasts..?? If so then maybe that will give us some idea.

At some point the company will do an offering or private placement and start raising money.

[daemon57]

The Corporate Actions have been approved by the board of directors of the Company and by holders of a majority of the outstanding shares of common stock of the Company.

That should have been an easy vote.. what is there less than a hands worth of members in the whole company (98%+ held by insiders)?

[Chuckles759]

Thank you for pointing that out.

I was distracted by more alarming items in the 10-Q.

[Big Brother]

Board name will change once it's processed/approved by FINRA and shows up on the Daily List.

[Big Brother]

The Company has submitted a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (FINRA) Rule 6490 (the “Corporate Action Notice”) on October 20, 2021, in connection with a proposed change of the Company’s name to Rovida Therapeutics, Inc. and the redomicile of the Company from Nevada to Delaware. The Corporate Actions have been approved by the board of directors of the Company and by holders of a majority of the outstanding shares of common stock of the Company. The Corporate Actions will be effectuated immediately following FINRA’s review thereof.

https://www.otcmarkets.com/filing/html?id=15376679&guid=I3vwkpv1YGIyOth

[Chuckles759]

Shouldn't the board name reflect this name change?

Can you point me to the SEC filing for the name change?

Same CUSIP as Regnum Corp?

Why is Anne Kirby signing filings as CEO, Regnum Corp ?

https://www.sec.gov/ix?doc=/Archives/edgar/data/1716324/000147793222000165/rgmp_8k.htm

Don't see what you're talking about.

[Big Brother]

OK, this may be a stretch but I am going to go out on a limb and say that is not the correct website any longer.....lol.

Considering that the name of Regnum Corp changed to 'Rovida Therapeutics'(as of Oct 2021).....and rovidatx.com was registered in Sept 2021, according to an ICANN
lookup, this seems like the most logical possibility for a new website.

Nothing there yet though.

[daemon57]

I found a bunch of OTHER STUFF

Need to thoroughly digest and further DD this 'other stuff'.

[Chuckles759]

I'm trying to do some DD on this ticker....

Their D&B entry has a website listed....

https://www.dnb.com/business-directory/company-profiles.regnum_corp.f493da72bb378fe76f3f6c54f0faa85b.html

Which points to http://www.regnumcorp.com/

Has anyone found the "Investor Relations" link on there....I found a bunch of OTHER STUFF....and kept looking for the IR info....but....I kept finding OTHER STUFF....

[Chuckles759]

And did you know that Sevenscore / Regnum is headed up by the same person operating out of the same shared office space in NYC ?

[purdue]

Law of supply and demand. There is no supply. It looks like only 270k m/l available. And no one is selling.

[daemon57]

I am slightly worried to paint the tape if I purchase 200 shares. No joke.

[Chuckles759]

Anyone know anything about the CEO, Director, Janitor, etc of Regnum?

Anne Kimberly....she's like 40yo and was a Pfizer saleslady....

[Chuckles759]

Any idea how big this can go with only 2K shares volume?

No options...no calls...no puts....????

[daemon57]

RGMP go big or go home.

[daemon57]

0.76 ? 0.06 (8.57%) -- hard to do TA on a stock with such low volume.

[daemon57]

When is this graduating to OTCBB?

[daemon57]

Lets go make some dough!

[Chuckles759]

I'm trying to still figure out where this RGMP is going.

Did anyone take the time to compare the 10Q originally filed 30Jun21 to the amended one filed on 30Sep21 ?

http://edgar.secdatabase.com/1709/147793221008762/filing-change.htm
RED = Old, GREEN = Revised, WHITE = Unchanged

The 30Jun21 filing on its own:
http://www.sec.gov/Archives/edgar/data/0001716324/000147793221006045/0001477932-21-006045-index.htm

The 30Sep21 filing on its own:
http://www.sec.gov/Archives/edgar/data/0001716324/000147793221008762/0001477932-21-008762-index.htm

On 30Jun21 it was doom & gloom. No end in sight. Serious concerns of continued operation. Some other drug - SSP-002?

Then 30Sep21 it was all cherries and whipped cream....and sprinkles too. Big outlook turn around....and pretty much the two main factors were:
- Leronlimab the only drug they market for
- Cancellation of Sevenscore merger with Regnum being survivor

Not sure how the price continues to stay inflated....with Hopenium?

[Garyst]

Nice grab!

[1TIMEPLEASEGOUPPPPP]

YES SIR~ MY .40Z AND .50Z WERE NICE GIFTZZZ~ THIS CAN EASILY SEE $5 FAST~$RGMP

[Garyst]

Getting some hits now

[Garyst]

Welcome.

[1TIMEPLEASEGOUPPPPP]

TOOK A STARTER HERE GARY ON THE PULLBACK FROM THE OTHER DAY~ LOOKZZZ THIN~ CAN SEE MULTI- DOLLARZZZZ INDEED~ $RGMP

[Garyst]

Light volume. Be patient. Moves on air

[SmittyInvestor]

Shareholders? bigbrother just explained there are no real shareholders, this is Thin as in just a few shareholders, as almost no trading available.

One Majority shareholder who did the deal because they wanted to use this shell company to realize the value of selling an HIV drug. If they keep this selling agreement in a private company what are their options for raising money to fund everything? there have much better chance of raising $30-50mil in the public market.

The share structure/ownership is one that we will be riding the majority owner's coattails. They will control what is going on. From what I see they will promote this HIV drug to make themselves alot of money in the public markets.

Again, clean shell at $15mil market cap offers little downside in my opinion

I am surprised you are even watching this stock.

[Saving Grace]

The filing states otherwise. Regnum bears the cost of just about everything while the others reap the reward. The agreement is shady at best with no real benefit to share holders from what I see. Shareholders were sold out, plain and simple.

https://www.otcmarkets.com/filing/conv_pdf?id=15470060&guid=8DvwkKt5C5rZOth

[Itchy palm]

Thanks read it sounds like HIV which is big by itself

[SmittyInvestor]

thanks for the note ted, big dollars for drug in HIV but it will be adapted to other items as doctors learn more about what it does.

Therapeutics and antiviral drugs will grow as more money flows into this space. The key will be whether the early patent holders of the lab discoveries can fund their discoveries into the commercial markets to help people. Most do not and have to do deals/sell off something to make progress in the govt health bureaucracy.

That is why cydy has to do deals as they cant fund everything, which will end up being good for regnum.

[Big Brother]

Sounds that way in the original agreement but not 100% sure as there is a lot of legalese in there.

https://www.sec.gov/Archives/edgar/data/1175680/000119312520004683/d855842dex105.htm

[Itchy palm]

Is that for the HIV only?

[Big Brother]

Yep, I mean the o/s and float of CYDY are growing at incredible levels.....RGMP will get 50% of the net sales of Leronlimab, and CYDY gets 50%.....the clean share structure of RGMP just looks way more appealing to me.

As you say, there will likely be an offering at some point, I dont think they are going to be able to raise the money they need through the usually OTC way...convertible debt.

So IMO, I would not be surprised at all, given the apparent massive investor interest in Leronlimab(considering CYDYs volume and market cap).....that we could even eventually see them find an investment bank to underwrite an offering of $40M or more and get them off the OTC and to the big boards....that seems certainly plausible to me IMO.

[Garyst]

Decent bids in the .60 range.

[SmittyInvestor]

Big brother explained there is no front loading so what else can you say on this?
The PR release looks legit, no over hype, just saying the sales agreement for whole US was transferred to another company, one that is public where we can participate in the future growth instead of a private company.

Also, in the penny market, a clean shell nowadays is easily worth $15mil market cap and more if they can bring millions of tax losses forward for the new company to keep future profits.

Liquidity/price spread maybe an issue as bigBrother mentioned so investors should welcome more shares via an offering after the price goes up. This is a great situation where having the money to fund everything will actually HELP shareholder value instead of dilute it.

In 6 months this company will look completely different and much more valuable than the $15mil market cap today
my opinion is Buy below a $60mil cap

[Garyst]

Well said!

[halbroke1]

RGMP $$$ MASSIVE RUNNER HERE...PROBABLY $10.00+ WILL COME FAST.

[goingUPagain]

Can we see $5 soon .. float is so low!

[Big Brother]

Agree 100%.....and it's exactly my thinking as well, at least one part of it for sure.

I mean it's very possible there may be a bigger plan at play, however, I personally believe the transfer of rights from Vyera/Sevenscore to RGMP was to prepare for the future fund raising efforts to commercialize Leronlimab.

However, it could also be one part, protecting a valuable asset, in the event of a Vyera BK as well.

It's no secret Vyera is in trouble, with both the $40 million FTC settlement....and an FDA-approved generic cutting into the Daraprim bottomline.

If they have to file BK and lose Daraprim, it stings a lot less for Phoenixus, if/when Leronlimab gets FDA approval...as Regnum/Cytodyn will make a lot of money together.

Just my opinion.

[Big Brother]

Exactly, that comment is beyond stupid on so many levels, it's almost inconceivable....lol...but then again this is iHub....so...

Good grief, the trading began @ .60 on Monday. I followed the entire trading on Monday, I have been following this ticker for 2 years..... and have been the high bidder a hell of LOT of that time.

In fact I've been the high bidder on L2 for probably the last 6 months and taking any paltry scraps I could get on the bid....and its been like pulling teeth....I'd get a couple hundred shares...wait a few weeks or months, maybe get a couple hundred or 2K more...wait another few weeks...another couple hundred.....lol.

I wish I could have loaded up cheap but I could never get much of anything and the spread was always too massive to slap the ask.....not to mention, it was soooo incredibly illiquid.

[Big Brother]

Before the big volume on Monday, From July 2021 to then, RGMP had traded about a whopping 12,700 shares in over 6 months.

Yes, there was a LOT of volume on Monday, but you could not really frontload cheap, the big % gain was very misleading. RGMP was illiquid and had a huge spread of .15 X .60 for a long, long time....there were no shares available to frontload cheap. The ONLY reason it looked like there was that huge gain, was because it a had gotten bid whacked for 5K shares @ .15 several days before the stock finally got actually some volume.

Yes, some people did get whacked some .30s and .40s on Monday, that low of .23 on Monday was a 100 share trade early on in the day. The stock quickly ran to $1.00 in the AM, on minimal volume, from the .60 cent ASK it had, that I mentioned early. Then a small wave of .30s- .50s whacked it back down......then it took off again in the latter part of the afternoon...and went back over $1.00.

So no, there was no 'cheap' frontloading of any kind.

[Garyst]

Where is there any volume in recent past suggesting front loading?

[Saving Grace]

This is a front loaded Pump and Dump and no promotion can undue the truth. It's covered in the filings I just posted with links.

There is nothing here, it's the most slick and shady agreement I have ever read. All smoke and mirrors that is explained in the filings in black and white.

[Saving Grace]

Look out below! Filings declare 100% Pump&Dump

Quote:
On January 3, 2022, Regnum Corp. (“Regnum”), CytoDyn Inc. (“CytoDyn”), and SevenScore Pharmaceuticals, LLC (“SevenScore”) entered into an
Assignment and Assumption Agreement (“Assignment”) of the Commercialization and License Agreement (the “License Agreement”) and a Supply Agreement
(the “Supply Agreement”) executed between Vyera Pharmaceuticals, LLC, a Delaware limited liability company (“Vyera”) and CytoDyn on December 17, 2019.
Through the Assignment, Regnum has the exclusive right to commercialize pharmaceutical preparations containing leronlimab (PRO 140) (the “Product”) for
treatment of HIV in humans (the “Field”) in the United States (the “Territory”). In exchange for these agreements SevenScore will receive 4,094,023 shares of
Regnum
Pursuant to the terms of the License Agreement, and subject to the conditions set forth therein, Regnum will bear the cost of, and be responsible for,
among other things, commercializing the Product in the Territory and will use commercially reasonable efforts to commercialize the Product in the Field in the
Territory. Under the terms of the License Agreement, CytoDyn is permitted to license the Product outside of the Territory for uses in the Field or outside the Field
or inside the Territory for uses outside of the Field.
Regnum is obligated to pay CytoDyn potential milestone payments upon certain regulatory and sales-based milestones. In addition, during the term of the
agreement, Regnum is obligated to pay CytoDyn a royalty equal to 50% of the Regnum’s gross profit margin from Product sales (defined in the License
Agreement as “Net Sales”) in the Territory. The royalty is subject to reduction during the Royalty Term after patent expiry and expiry of regulatory exclusivity.
Following expiration of the Royalty Term, Regnum will continue to maintain non-exclusive rights to commercialize the Product.
The License Agreement will expire upon the expiration of the Royalty Term. The “Royalty Term” means the period beginning on the date of the first
commercial sale of the Product and ends on the latest of (i) the expiration of the last valid claim of the patents covering the Product, (ii) ten years after the first
commercial sale of the Product, (iii) the expiration of regulatory exclusivity for the Product and (iv) the Biosimilar Entry Date (as defined in the License
Agreement). The License Agreement may be terminated by either party for material breach, upon a party’s insolvency or bankruptcy, or for a safety concern or
clinical failure.
Regnum has the right to terminate the License Agreement (i) on or after the second anniversary of the effective date of the License Agreement upon
written notice to CytoDyn in the event the approval (“Regulatory Approval”) by the U.S. Food and Drug Administration of the Biologics License Application for
the Product for the manufacture and sale of the Product in the Territory for the Initial Indication (as defined in the License Agreement) has not been received by
such second anniversary, (ii) if Regnum fails to achieve certain aggregate Net Sales (as defined in the License Agreement) of the Product during the period
beginning on the date of first commercial sale and ending on the date that is two years from the date of the first commercial sale, and (iii) at Regnum’s convenience
following the second anniversary of the first commercial sale of the Product with 180 days’ written notice.
The License Agreement also contains customary representations, warranties, and covenants by both parties, as well as customary provisions relating to
indemnification, confidentiality, and other matters.
Supply Agreement
Pursuant to the Supply Agreement, CytoDyn has agreed to supply to Regnum the Product for commercialization under the License Agreement.
The Supply Agreement contains customary representations, warranties, and covenants, including representations and warranties relating to compliance of the
Product with specifications and applicable governmental rules and covenants with respect to the rejection of delivered Product and nonconforming Product, product recalls and regulatory communications.
The Supply Agreement will expire at the expiration of the Royalty Term, provided that Regnum shall have the right, in its sole discretion, to extend the
term of the Supply Agreement for so long as Regnum agrees to continue to pay CytoDyn an agreed-upon royalty payment.


Front loaded sell off scam!

Quote:
THIS CONTRIBUTION AGREEMENT (this “Contribution Agreement”) is made effective as of January 3, 2022 (the “Effective Date”), notwithstanding
the actual date of execution hereof, by and among SevenScore Pharmaceuticals, LLC, a Delaware limited liability company (“SevenScore”), Regnum Corp., a
Nevada corporation (“Regnum”) and Phoenixus AG, a corporation organized under the laws of Switzerland and holder of (a) 99% of the issued and outstanding
shares of Regnum, and (b) 100% of the issued and outstanding membership interest units of SevenScore (“Phoenixus”).

https://www.otcmarkets.com/filing/conv_pdf?id=15470060&guid=8DvwkKt5C5rZOth

[Garyst]

Mon 890% peak on 230k @ the time. No shares here!

[Garyst]

100k AM buying volume & $2++++

[Garyst]

Hit 890% $1.43 HOD yesterday and green Again today!

[Garyst]

https://www.otcmarkets.com/stock/RGMP/news/story?e&id=2098511

[Garyst]

RGMP Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV"

[Garyst]

RGMP 290k unrestricted shares! $3+ coming

[Garyst]

RGMP # 2 on the breakout boards!